At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BMEA Biomea Fusion, Inc.
Market Closed 03-28 16:00:00 EDT
2.30
-0.19
-7.63%
盘后2.30
+0.000.00%
18:40 EDT
| High2.50 | Low2.29 | Vol341.96K |
| Open2.46 | D1 Closing2.49 | Amplitude8.43% |
| Mkt Cap83.35M | Tradable Cap64.55M | Total Shares36.24M |
| T/O806.21K | T/O Rate1.22% | Tradable Shares28.06M |
| P/B1.10 | ROE-104.51% | EPS-4.00 |
| 52wk High16.29 | 52wk Low2.27 | P/E-0.57 |
| Dividend0.00 | Div.Yield0.00 | ROA-56.38% |
Loading ...
Biomea Fusion Inc expected to post a loss of 92 cents a share - Earnings Preview
Reuters · 03-28 12:52
Biomea Fusion Appoints Interim CEO Amid Leadership Changes
TIPRANKS · 03-27 20:55
Biomea Fusion Names Hitchcock as Interim CEO, Succeeding Butler
Dow Jones · 03-25
BRIEF-Biomea Fusion Says Mick Hitchcock Named Interim CEO Replacing Thomas Butler
Reuters · 03-25
Biomea Fusion Announces Leadership Transition
THOMSON REUTERS · 03-25
Biomea Fusion Inc - Mick Hitchcock to Succeed Thomas Butler as Interim CEO Effective Immediately
THOMSON REUTERS · 03-25
Press Release: Biomea Fusion Announces Leadership Transition
Dow Jones · 03-25
Biomea Fusion announces presentation of icovamenib preclinical, clinical data
TipRanks · 03-25
Scotiabank Keeps Their Buy Rating on Biomea Fusion (BMEA)
TIPRANKS · 03-25
Barclays Sticks to Its Hold Rating for Biomea Fusion (BMEA)
TIPRANKS · 03-25
Biomea Fusion Price Target Maintained With a $40.00/Share by HC Wainwright & Co.
Dow Jones · 03-24
Freightos And 2 Other Penny Stocks Worth Watching
Simply Wall St. · 03-24
Freightos And 2 Other Penny Stocks Worth Watching
Biomea Fusion Is Maintained at Buy by D. Boral Capital
Dow Jones · 03-24
Biomea Fusion Inc - Icovamenib Shows Sustained Reduction in Hba1c and Beta-Cell Function
THOMSON REUTERS · 03-24
Biomea Fusion Inc - Icovamenib Enhances Impact of Glp-1 Based Therapeutic Agents
THOMSON REUTERS · 03-24
Icovamenib Treatment in Patients With Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-Cell Function With a 53% Mean Increase in C-Peptide Levels 3 Months After Last Dose
THOMSON REUTERS · 03-24
Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose
GlobeNewswire · 03-24
Biomea Fusion Insiders Recover Some Losses, Which Stand At US$91k
Simply Wall St. · 03-22
Biomea Fusion Is Maintained at Buy by D. Boral Capital
Dow Jones · 03-19
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 03-03
Introduction
Company Name.
Biomea Fusion, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
2021-04-16
Main Business:
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Issue price:
17.00
Invest in Global Markets with Tiger Brokers!Open App